179 related articles for article (PubMed ID: 9667644)
1. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status.
Beauregard DA; Thelwall PE; Chaplin DJ; Hill SA; Adams GE; Brindle KM
Br J Cancer; 1998 Jun; 77(11):1761-7. PubMed ID: 9667644
[TBL] [Abstract][Full Text] [Related]
2. Effects of combretastatin on murine tumours monitored by 31P MRS, 1H MRS and 1H MRI.
Maxwell RJ; Nielsen FU; Breidahl T; Stødkilde-Jørgensen H; Horsman MR
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):891-4. PubMed ID: 9845116
[TBL] [Abstract][Full Text] [Related]
3. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability.
Beauregard DA; Hill SA; Chaplin DJ; Brindle KM
Cancer Res; 2001 Sep; 61(18):6811-5. PubMed ID: 11559555
[TBL] [Abstract][Full Text] [Related]
4. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate.
Chaplin DJ; Pettit GR; Hill SA
Anticancer Res; 1999; 19(1A):189-95. PubMed ID: 10226542
[TBL] [Abstract][Full Text] [Related]
5. Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours.
Holwell SE; Cooper PA; Grosios K; Lippert JW; Pettit GR; Shnyder SD; Bibby MC
Anticancer Res; 2002; 22(2A):707-11. PubMed ID: 12017147
[TBL] [Abstract][Full Text] [Related]
6. Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS.
Beauregard DA; Pedley RB; Hill SA; Brindle KM
NMR Biomed; 2002 Apr; 15(2):99-105. PubMed ID: 11870905
[TBL] [Abstract][Full Text] [Related]
7. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
Dark GG; Hill SA; Prise VE; Tozer GM; Pettit GR; Chaplin DJ
Cancer Res; 1997 May; 57(10):1829-34. PubMed ID: 9157969
[TBL] [Abstract][Full Text] [Related]
8. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug.
Grosios K; Holwell SE; McGown AT; Pettit GR; Bibby MC
Br J Cancer; 1999 Dec; 81(8):1318-27. PubMed ID: 10604728
[TBL] [Abstract][Full Text] [Related]
9. Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats.
Thoeny HC; De Keyzer F; Chen F; Ni Y; Landuyt W; Verbeken EK; Bosmans H; Marchal G; Hermans R
Radiology; 2005 Mar; 234(3):756-64. PubMed ID: 15734932
[TBL] [Abstract][Full Text] [Related]
10. Tumor physiologic response to combretastatin A4 phosphate assessed by MRI.
Zhao D; Jiang L; Hahn EW; Mason RP
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):872-80. PubMed ID: 15936572
[TBL] [Abstract][Full Text] [Related]
11. Vascular disrupting agent in pancreatic and hepatic tumour allografts: observations of location-dependent efficacy by MRI, microangiography and histomorphology.
Yin T; Liu Y; Peeters R; Feng Y; Yu J; Himmelreich U; Oyen R; Ni Y
Br J Cancer; 2017 Nov; 117(10):1529-1536. PubMed ID: 28910821
[TBL] [Abstract][Full Text] [Related]
12. Early effects of combretastatin A4 phosphate assessed by anatomic and carbogen-based functional magnetic resonance imaging on rat bladder tumors implanted in nude mice.
Thomas CD; Walczak C; Kaffy J; Pontikis R; Jouanneau J; Volk A
Neoplasia; 2006 Jul; 8(7):587-95. PubMed ID: 16867221
[TBL] [Abstract][Full Text] [Related]
13. The effect of combretastatin A4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours.
Chen G; Horsman MR; Pedersen M; Pang Q; Stødkilde-Jørgensen H
Acta Oncol; 2008; 47(6):1071-6. PubMed ID: 18770061
[TBL] [Abstract][Full Text] [Related]
14. 31P-magnetic resonance spectroscopy and 2H-magnetic resonance imaging studies of a panel of early-generation transplanted murine tumour models.
Robinson SP; van den Boogaart A; Maxwell RJ; Griffiths JR; Hamilton E; Waterton JC
Br J Cancer; 1998 Jun; 77(11):1752-60. PubMed ID: 9667643
[TBL] [Abstract][Full Text] [Related]
15. The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS.
Breidahl T; Nielsen FU; Stødkilde-Jørgensen H; Maxwell RJ; Horsman MR
Acta Oncol; 2006; 45(3):306-16. PubMed ID: 16644574
[TBL] [Abstract][Full Text] [Related]
16. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging.
Galbraith SM; Maxwell RJ; Lodge MA; Tozer GM; Wilson J; Taylor NJ; Stirling JJ; Sena L; Padhani AR; Rustin GJ
J Clin Oncol; 2003 Aug; 21(15):2831-42. PubMed ID: 12807936
[TBL] [Abstract][Full Text] [Related]
17. The combined measurement of blood flow and metabolism in RIF-1 tumours in vivo. A study using H2 flow and 31P NMR spectroscopy.
Bhujwalla ZM; Tozer GM; Field SB; Proctor E; Busza A; Williams SR
NMR Biomed; 1990 Aug; 3(4):178-83. PubMed ID: 2206850
[TBL] [Abstract][Full Text] [Related]
18. Pre-treatment energy status of primary rat tumours as the best predictor of response to 5-fluorouracil chemotherapy: a magnetic resonance spectroscopy study in vivo.
Lemaire LP; McSheehy PM; Griffiths JR
Cancer Chemother Pharmacol; 1998; 42(3):201-9. PubMed ID: 9685055
[TBL] [Abstract][Full Text] [Related]
19. Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models.
Hill SA; Chaplin DJ; Lewis G; Tozer GM
Int J Cancer; 2002 Nov; 102(1):70-4. PubMed ID: 12353236
[TBL] [Abstract][Full Text] [Related]
20. Modification of the 31P magnetic resonance spectra of a rat tumour using vasodilators and its relationship to hypotension.
Tozer GM; Maxwell RJ; Griffiths JR; Pham P
Br J Cancer; 1990 Oct; 62(4):553-60. PubMed ID: 2223572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
